+70%

est. 2Y upside i

AerospaceSeries C

From life-saving pharmaceuticals to more powerful fiber optics, there is a world of products used on Earth today that can only be manufactured in space. Varda is designing and building the infrastructure needed to make low Earth orbit accessible, from in-orbit production equipment to reliable reentry capsules.

Rank

#1148

Sector

Aerospace & In-Space Manufacturing

Est. Liquidity

~3Y

Data Quality

Data: High

Varda presents a moderate upside opportunity, driven by its innovative technology in microgravity pharmaceutical manufacturing and hypersonic re-entry services.

Last updated: March 10, 2026

Bull (30%)+200%

Varda achieves significant breakthroughs in microgravity pharmaceutical manufacturing, securing initial FDA approvals for space-produced drugs and establishing lucrative royalty agreements with major pharmaceutical companies. The 'reentry-as-a-service' for hypersonic testing also scales rapidly with increased government contracts, pushing revenue to over $200M by 2028 and justifying a $3.6B valuation (3x current) as a market leader in a nascent, high-growth sector.

Base (45%)+50%

Varda continues to execute on its mission cadence, successfully launching and returning capsules for both pharmaceutical R&D and hypersonic testing. Regulatory approvals for space-manufactured drugs progress steadily but slowly, and initial commercial agreements are established. Revenue grows to approximately $75M by 2028, leading to a $1.8B valuation (1.5x current) as the company solidifies its niche but faces ongoing capital intensity and competitive pressures.

Bear (25%)-50%

Significant regulatory delays for FDA approvals or FAA re-entry licenses, coupled with slower-than-expected market adoption for space-manufactured pharmaceuticals, hinder Varda's growth. Incumbents or well-funded competitors gain traction, eroding Varda's market share. Revenue stalls below $30M, leading to a down round or a flat exit at $0.6B (0.5x current), significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

27%

Investors hold $329M in liquidation preferences, meaning in an exit at or below $1.2B, common stock holders would see significantly reduced returns or nothing until these preferences are paid out.

Dilution Risk

moderate

As a Series C company with ambitious expansion plans, Varda will likely require additional funding rounds, posing a moderate risk of further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Varda's shares at this time.

Other — 2 roles

View all 2 open roles at Varda →

Last updated: March 9, 2026

Questions to Ask at the Interview

Strategic questions based on Varda's data — designed to show you've done your homework.

  • 1

    “Given the high capital intensity of space manufacturing and your current valuation, how does Varda plan to achieve profitability and manage future funding needs without excessive dilution for common shareholders?”

  • 2

    “With Redwire operating on the ISS and larger players like Blue Origin developing commercial space stations, what specific strategies will Varda employ to maintain its competitive moat and differentiate its vertically integrated re-entry capabilities?”

  • 3

    “Considering the significant regulatory hurdles for both FAA re-entry and FDA approval of space-manufactured drugs, what is the realistic timeline and key milestones for achieving commercialization and generating substantial royalty revenue from pharmaceuticals?”

Community

Valuation Sentiment

Our model estimates +70% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.